Straight answers, before you call.

Quickly — new patients are typically seen within days, not weeks or months. Request a time and the office will email you back promptly to confirm. Fast access to the physician is part of how this practice is built.

No referral is required to request an appointment. Some insurance plans may require one for coverage, which we'll help you sort out, but you can reach out to us directly.

Yes. Richmond Brain & Behavior is currently accepting new patients for both general psychiatry and interventional treatments.

You'll see Dr. Beasley. He personally evaluates every patient, sets and adjusts your treatment protocol, supervises Spravato monitoring, manages every prescription, and signs every chart. A trained clinical team may deliver your TMS sessions, but the physician is on-site, reviews how you respond, and directs the course — you're not handed off to a rotating cast or a mid-level on a script.

Yes. Roughly half of general psychiatry visits are by telehealth. Interventional treatments — Deep TMS, Spravato, and IV ketamine — are in-person, since they're delivered in the office.

A list of medications you've tried (and how they worked), any relevant records or prior treatment history, your insurance information, and your questions. For treatment-resistant depression, knowing which antidepressants you've tried is especially useful.

Treatment-resistant depression, OCD, anxiety, PTSD, late-life depression, bipolar disorder, opioid and alcohol use disorder, ADHD, and general psychiatric medication management.

The general rule for depression is that you've tried two or more antidepressants without getting well; for OCD, that medication and therapy haven't been enough. The real answer comes from an evaluation, where Dr. Beasley reviews your history and safety screens and tells you directly.

The coil. Standard TMS (such as NeuroStar) uses a figure-8 coil; BrainsWay Deep TMS uses an H-coil that produces a deeper, broader magnetic field. Dr. Beasley treats with both BrainsWay coils — the H1 for depression and the H7 for OCD.

Yes — here. Dr. Beasley treats OCD with the BrainsWay H7 coil, FDA-cleared for OCD in 2018. The OCD protocol uses a different coil, a different brain target, and a brief symptom provocation before each session; see the TMS for OCD page for how it works and who it suits.

Many people start noticing change a few weeks into the course rather than right away. A standard course is about 36 sessions over several weeks, plus a taper. Some respond earlier, some later.

About 20 minutes for a standard session, and less with theta burst (iTBS). You're awake the whole time and can drive yourself and return to your day immediately afterward.

Accelerated protocols deliver multiple sessions per day over fewer days, rather than spreading the course across weeks. They're appropriate for some patients but not everyone — Dr. Beasley decides with you whether it fits.

You'll feel a tapping sensation on your scalp and hear clicking during the pulses. Some people get scalp discomfort or a headache early in the course, which usually eases. There's no sedation and no recovery time.

Many insurers cover Deep TMS for treatment-resistant depression, and increasingly for OCD, usually with prior authorization. We verify your specific coverage before you start a course.

There are safety screens — for example, certain implanted metal or electronic devices near the head are contraindications. Dr. Beasley reviews all of this at your evaluation.

Spravato is esketamine, delivered as a nasal spray, FDA-approved for treatment-resistant depression. It's administered in the office under supervision, not taken home.

Many plans cover Spravato for treatment-resistant depression, usually with prior authorization. We verify benefits through the specialty-pharmacy process before you begin.

The two-hour in-office monitoring is required because esketamine can cause temporary sedation, dissociation, and blood-pressure changes. It's a safety requirement, and you can't drive afterward — plan for a ride home.

Both are ketamine-family treatments. Spravato (esketamine) is an FDA-approved nasal spray given under a REMS program, so it more often has an insurance pathway. IV ketamine is the full ketamine molecule given intravenously, which allows finer dose control, and is used off-label — so it's typically self-pay. Head-to-head evidence is limited, and the better choice usually comes down to your history and what you can realistically sustain. We offer both and will help you choose.

Twice weekly for the first 4 weeks during the induction phase, then weekly for 4 weeks during maintenance, spacing out as appropriate afterward. Your schedule is individualized.

Adults with treatment-resistant depression — generally those who've tried two or more antidepressants without adequate response — who can attend in-office sessions and the two-hour monitoring, and who clear the medical safety screen. It is given with an oral antidepressant.

No. Ketamine is FDA-approved as an anesthetic; using it for depression is off-label. Off-label prescribing is legal and common across medicine when clinical judgment supports it, but it has two direct consequences: insurance generally does not cover it, and the treatment does not carry the FDA's review of that specific use. Spravato (esketamine) is the FDA-approved option for treatment-resistant depression, given with an oral antidepressant.

Generally no, because the use is off-label — infusions are typically self-pay. Spravato is the route with an insurance pathway, usually with prior authorization. If cost is a deciding factor, say so early: it legitimately changes which treatment is the better choice for you.

No. Ketamine causes temporary effects on alertness and perception, so you cannot drive after a session. Plan for someone to take you home each time.

There isn't a universal winner. They differ in mechanism, schedule, regulatory status, and payment. Head-to-head evidence is limited. Deep TMS is FDA-cleared and non-drug; Spravato is FDA-approved esketamine, given with an oral antidepressant; IV ketamine is off-label for depression and generally self-pay. The better choice is the one that fits your history and what you can sustain.

Medication-assisted treatment uses FDA-approved medication — buprenorphine (Suboxone) or monthly Sublocade — to treat opioid use disorder by controlling cravings and withdrawal. It's the standard of care.

Yes. Substance use treatment records carry additional federal confidentiality protection under 42 CFR Part 2, beyond ordinary medical privacy. Your treatment isn't shared casually.

Suboxone (buprenorphine) is a daily film or tablet. Sublocade is a monthly injectable form of buprenorphine given in the office. Dr. Beasley helps you choose which fits your life.

No. MAT is designed to help you stabilize. You don't need to have already quit, and you don't need to 'hit bottom' to begin.

3111 Northside Avenue, Suite 200B, Richmond, VA 23228, in the Northside area.

We work with a range of plans, including in-network access facilitated through Headway, and offer cash-pay. Spravato runs through a specialty-pharmacy path. Tell us your insurer when you request an appointment and we'll confirm coverage.

Use the Request an appointment form on the site, or call (804) 476-8274. You request a time; the office emails you back promptly to confirm.

Monday through Friday, 9:00 a.m. to 5:00 p.m. Please confirm current hours with the office.